A few days ago we brought you news of a UK rival to Acomplia which is producing astounding results in Phase I clinical trials. Well, now we can report that Taranabant, the Acomplia rival being developed by Merck, is entering the final stages of its Phase III clinical trial. Around 2400 patients have been taking part in the international two year trial and the drug company expects to file for approval in Spring 2008.
Unlike the Acomplia clinical trials, we have not been constantly updated with news from the trials although we have heard on the grapevine that this drug could perform significantly better than Acomplia but this remains to be seen.
As soon as we have more details, we will be post another story.